Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 19/20 | 0.64 |
| ▸ | CRBN | Q96SW2 | 19/20 | 0.64 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.61 |
| ▸ | TNF | P01375 | 1/20 | 0.61 |
| ▸ | IL1B | P01584 | 1/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.61 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24817881 | 0.93 | DDB1 (0.60) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL22464977 | 0.92 | DDB1 (0.61) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL22465008 | 0.92 | DDB1 (0.61) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL23300940 | 0.91 | CRBN (0.62) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL22464574 | 0.90 | DDB1 (0.59) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL25813908 | 0.89 | DDB1 (0.62) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL26925479 | 0.88 | CRBN (0.57) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL30732014 | 0.88 | CRBN (0.57) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL24123474 | 0.87 | DDB1 (0.60) | DDB1CRBNIKZF3TNFIL1B | |
| SCHEMBL22511604 | 0.87 | CRBN (0.67) | DDB1CRBNIKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137500-A1 | KINASE INHIBITION AND DEGRADATION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-119613483-A | Degradation agent for targeting BET and/or CBP/p300 protein and application thereof | 国科宁波生命与健康产业研究院 | 2025-03-14 | — | — | CN | disclosed |
| US-20240317711-A1 | AURKA SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA INC. (KR) | 2024-09-26 | — | — | US | disclosed |
| WO-2022270987-A1 | AURKA SELECTIVE DEGRADATION INDUCING COMPOUND | (주) 업테라 | 2022-12-29 | — | — | WO | disclosed |
| WO-2022251224-A1 | WEE1 INHIBITORS AND METHODS FOR TREATING CANCER | RECURIUM IP HOLDINGS, LLC (US) | 2022-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317711-A1 | AURKA SELECTIVE DEGRADATION INDUCING COMPOUND | STUB1, AURKA, XIAP | DDB1 377/4885CRBN 757/4885IKZF3 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.